高级检索
当前位置: 首页 > 详情页

Early Course of Inflammatory Bowel Disease in a Population-Based Inception Cohort Study From 8 Countries in Asia and Australia.

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Medicine and Therapeutics, Institute of Digestive Disease, State Key Laboratory of Digestive Diseases, Li KaShing Institute of Health Science, 17Department of Pediatrics, Chinese University of Hong Kong, Hong Kong, China [2]The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China [3]St Vincent’s Hospital and University of Melbourne,Melbourne, Victoria, Australia [4]Faculty of Medicine, University of Kelaniya, Regama, Sri Lanka [5]National University Hospitalof Singapore, Singapore, Singapore [6]Singapore General Hospital, Singapore, Singapore [7]University of Malaya MedicalCentre, Kuala Lumpur, Malaysia [8]West China Hospital, Sichuan University, Chengdu, China [9]Xijing Hospital, Fourth MilitaryMedical University, Xian, China [10]Maharaj Nakorn Chiangmai Hospital, Chiangmai, Thailand [11]Siriraj Hospital, Bangkok,Thailand [12]King Chulalongkorn Memorial Hospital, Bangkok, Thailand [13]Faculty of Medicine Universitas Indonesia/Dr. Cipto Mangunkusumo Hospital [14]Tseung Kwan O Hospital, Hong Kong, China [15]North District Hospital, Hong Kong, China [16]Alice Ho Miu Ling Nethersole Hospital, Hong Kong, China [18]Kiangwu Hospital, Macau, China [19]Hospital Conde SJanuario, Macau, China
出处:
ISSN:

关键词: ACCESS Natural History Risk Factor Treatment

摘要:
The incidence of inflammatory bowel disease (IBD) is increasing in Asia, but little is known about disease progression in this region. The Asia-Pacific Crohn's and Colitis Epidemiology Study was initiated in 2011, enrolling subjects from 8 countries in Asia (China, Hong Kong, Indonesia, Sri Lanka, Macau, Malaysia, Singapore, and Thailand) and Australia. We present data from this ongoing study. We collected data on 413 patients diagnosed with IBD (222 with ulcerative colitis [UC], 181 with Crohn's disease [CD], 10 with IBD unclassified; median age, 37 y) from 2011 through 2013. We analyzed the disease course and severity and mortality. Risks for medical and surgical therapies were assessed using Kaplan-Meier analysis. The cumulative probability that CD would change from inflammatory to stricturing or penetrating disease was 19.6%. The cumulative probabilities for use of immunosuppressants or anti-tumor necrosis factor agents were 58.9% and 12.0% for patients with CD, and 12.7% and 0.9% for patients with UC, respectively. Perianal CD was associated with an increased risk of anti-tumor necrosis factor therapy within 1 year of its diagnosis (hazard ratio, 2.97; 95% confidence interval, 1.09-8.09). The cumulative probabilities for surgery 1 year after diagnosis were 9.1% for patients with CD and 0.9% for patients with UC. Patients with CD and penetrating disease had a 7-fold increase for risk of surgery, compared with patients with inflammatory disease (hazard ratio, 7.67; 95% confidence interval, 3.93-14.96). The overall mortality for patients with IBD was 0.7%. In a prospective population-based study, we found that the early course of disease in patients with IBD in Asia was comparable with that of the West. Patients with CD frequently progress to complicated disease and have accelerated use of immunosuppressants. Few patients with early stage UC undergo surgery in Asia. Increasing our understanding of IBD progression in different populations can help optimize therapy and improve outcomes. Copyright © 2016 AGA Institute. Published by Elsevier Inc. All rights reserved.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2016]版:
大类 | 1 区 医学
小类 | 1 区 胃肠肝病学
最新[2023]版:
大类 | 1 区 医学
小类 | 1 区 胃肠肝病学
JCR分区:
出版当年[2016]版:
Q1 GASTROENTEROLOGY & HEPATOLOGY
最新[2023]版:
Q1 GASTROENTEROLOGY & HEPATOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者机构: [1]Department of Medicine and Therapeutics, Institute of Digestive Disease, State Key Laboratory of Digestive Diseases, Li KaShing Institute of Health Science, 17Department of Pediatrics, Chinese University of Hong Kong, Hong Kong, China [*1]Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong.
共同第一作者:
通讯作者:
通讯机构: [1]Department of Medicine and Therapeutics, Institute of Digestive Disease, State Key Laboratory of Digestive Diseases, Li KaShing Institute of Health Science, 17Department of Pediatrics, Chinese University of Hong Kong, Hong Kong, China [*1]Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43377 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号